This company listing is no longer active
RAP Stock Overview
ResApp Health Limited develops digital healthcare solutions to assist doctors and allow patients to diagnose and manage respiratory disease.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
ResApp Health Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.20 |
| 52 Week High | AU$0.21 |
| 52 Week Low | AU$0.048 |
| Beta | -0.42 |
| 1 Month Change | 7.90% |
| 3 Month Change | 17.14% |
| 1 Year Change | 153.09% |
| 3 Year Change | 2.50% |
| 5 Year Change | 192.86% |
| Change since IPO | -96.25% |
Recent News & Updates
Recent updates
Is ResApp Health (ASX:RAP) In A Good Position To Invest In Growth?
Dec 31
Is ResApp Health (ASX:RAP) In A Good Position To Invest In Growth?
Aug 26Here's Why We're Watching ResApp Health's (ASX:RAP) Cash Burn Situation
May 08Analysts Are Optimistic We'll See A Profit From ResApp Health Limited (ASX:RAP)
Feb 25Companies Like ResApp Health (ASX:RAP) Are In A Position To Invest In Growth
Dec 23Shareholder Returns
| RAP | AU Healthcare Services | AU Market | |
|---|---|---|---|
| 7D | 0% | 7.3% | 0.9% |
| 1Y | 153.1% | 60.7% | 5.7% |
Return vs Industry: RAP exceeded the Australian Healthcare Services industry which returned -22.6% over the past year.
Return vs Market: RAP exceeded the Australian Market which returned -8.2% over the past year.
Price Volatility
| RAP volatility | |
|---|---|
| RAP Average Weekly Movement | 17.6% |
| Healthcare Services Industry Average Movement | 8.1% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in AU Market | 17.5% |
| 10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: RAP's share price has been volatile over the past 3 months.
Volatility Over Time: RAP's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | n/a | Tony Keating | www.resapphealth.com.au |
ResApp Health Limited develops digital healthcare solutions to assist doctors and allow patients to diagnose and manage respiratory disease. The company offers ResAppDx, a smartphone-based acute respiratory disease diagnostic test; and SleepCheckRx, a smartphone application for at-home sleep apnoea screening. Its technology uses mathematical features for the diagnosis of pneumonia, asthma, and chronic obstructive pulmonary disease.
ResApp Health Limited Fundamentals Summary
| RAP fundamental statistics | |
|---|---|
| Market cap | AU$176.24m |
| Earnings (TTM) | -AU$7.10m |
| Revenue (TTM) | AU$3.81m |
46.3x
P/S Ratio-24.8x
P/E RatioIs RAP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RAP income statement (TTM) | |
|---|---|
| Revenue | AU$3.81m |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$3.81m |
| Other Expenses | AU$10.91m |
| Earnings | -AU$7.10m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0083 |
| Gross Margin | 100.00% |
| Net Profit Margin | -186.19% |
| Debt/Equity Ratio | 0% |
How did RAP perform over the long term?
See historical performance and comparison